News coverage about Portola Pharmaceuticals (NASDAQ:PTLA) has trended somewhat positive on Saturday, according to Accern Sentiment. The research firm identifies positive and negative news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Portola Pharmaceuticals earned a news sentiment score of 0.14 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 45.3414081691576 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

These are some of the media stories that may have impacted Accern Sentiment’s analysis:

Shares of Portola Pharmaceuticals (PTLA) opened at 54.95 on Friday. The stock’s market cap is $3.17 billion. Portola Pharmaceuticals has a 12-month low of $15.68 and a 12-month high of $67.10. The stock’s 50 day moving average is $58.25 and its 200-day moving average is $47.24.

Portola Pharmaceuticals (NASDAQ:PTLA) last announced its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($1.22) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.10) by ($0.12). Portola Pharmaceuticals had a negative net margin of 807.93% and a negative return on equity of 145.12%. The firm had revenue of $3.79 million during the quarter, compared to analysts’ expectations of $4.28 million. During the same period in the prior year, the company posted ($1.02) EPS. The company’s revenue for the quarter was down 10.4% compared to the same quarter last year. Equities analysts expect that Portola Pharmaceuticals will post ($4.83) EPS for the current year.

A number of equities research analysts have weighed in on the stock. Citigroup Inc. set a $51.00 price objective on shares of Portola Pharmaceuticals and gave the stock a “buy” rating in a report on Saturday, June 17th. Oppenheimer Holdings, Inc. increased their price target on shares of Portola Pharmaceuticals from $46.00 to $66.00 and gave the company an “outperform” rating in a report on Monday, June 26th. BidaskClub cut shares of Portola Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, August 4th. Credit Suisse Group set a $70.00 price target on shares of Portola Pharmaceuticals and gave the company a “hold” rating in a report on Thursday, August 10th. They noted that the move was a valuation call. Finally, William Blair reiterated an “outperform” rating on shares of Portola Pharmaceuticals in a report on Monday, June 26th. Four investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Portola Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $63.77.

ILLEGAL ACTIVITY NOTICE: “Somewhat Favorable News Coverage Somewhat Unlikely to Affect Portola Pharmaceuticals (PTLA) Share Price” was published by Daily Political and is the sole property of of Daily Political. If you are viewing this report on another site, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this report can be viewed at

In related news, EVP Tao Fu sold 5,812 shares of the company’s stock in a transaction dated Tuesday, July 18th. The shares were sold at an average price of $65.00, for a total value of $377,780.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO William Lis sold 269,299 shares of the company’s stock in a transaction dated Wednesday, June 28th. The shares were sold at an average price of $55.43, for a total transaction of $14,927,243.57. The disclosure for this sale can be found here. Insiders sold 589,656 shares of company stock valued at $32,818,131 in the last three months. 4.90% of the stock is currently owned by insiders.

About Portola Pharmaceuticals

Portola Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots.

Insider Buying and Selling by Quarter for Portola Pharmaceuticals (NASDAQ:PTLA)

Receive News & Ratings for Portola Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.